Risk of ischaemic stroke in thyrotoxic atrial fibrillation

doi:10.1111/cen.14061

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/32518

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32518

Title:	Risk of ischaemic stroke in thyrotoxic atrial fibrillation
Authors:	Zhih-Cherng Chen(陳志成) Nan-Chun Wu(吳南鈞) Chang, Chia-Li Chung-Han Ho(何宗翰) Liao, Chia-Te Chun-Yen Chiang(蔣俊彥) Chang, Wei-Ting
Contributors:	Chi Mei Med Ctr, Dept Cardiol Chia Nan Univ Pharm & Sci, Dept Pharm Chi Mei Med Ctr, Dept Cardiovasc Surg Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Chi Mei Med Ctr, Dept Med Res Southern Taiwan Univ Sci & Technol, Dept Biotechnol Natl Cheng Kung Univ, Coll Med, Inst Clin Med
Keywords:	Atrial fibrillation stroke thyrotoxicosis
Date:	2019-10
Issue Date:	2020-07-29 13:48:15 (UTC+8)
Publisher:	WILEY
Abstract:	Objective Atrial fibrillation (AF) is the most common cardiac complication of thyrotoxicosis and is strongly implicated in thromboembolic events. However, the incidence of stroke in thyrotoxic AF remains unclear. Herein, we aimed to investigate the risks of mortality and ischaemic stroke between patients with thyrotoxic AF and nonthyrotoxic AF. Designs and Methods From Taiwan's National Health Insurance Research Database, 1868 patients with the concomitant diagnoses of AF and thyrotoxicosis identified between 2001 and 2010 were compared to 7472 patients with nonthyrotoxic AF using propensity score matching for age, sex and comorbidities. Results There was no significant difference in either CHA(2)DS(2)-VASc score or anticoagulant usage between the groups. Alternatively, the thyrotoxic group contained more beta-blocker/digoxin users, whereas the nonthyrotoxic group contained more statin users. Patients with thyrotoxic AF exhibited lower risks of all-cause mortality (HR: 0.66, CI: 0.59-0.73, P < .0001) and ischaemic stroke (HR: 0.73, CI: 0.64-0.84, P < .0001) than those with nonthyrotoxic AF, especially thyrotoxic patients with CHA(2)DS(2)-VASc scores >= 1. Comorbidities, including diabetes, hyperlipidaemia, hypertension and coronary artery disease, contributed to all-cause mortality in patients with nonthyrotoxic AF; however, this effect was diminished in thyrotoxic AF. Conclusions Patients with thyrotoxicosis and AF have a lower risk of stroke than patients with nonthyrotoxic AF. Treatment for thyrotoxicosis is also crucial as the prescription of anticoagulants based on CHA2DS2-VASc scores.
Relation:	Clinical Endocrinology, v.91, n.4, pp.561-570
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles [Dept. of Hospital and Health (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
10.1111-cen.14061.pdf		643Kb	Adobe PDF	406	View/Open
index.html		0Kb	HTML	1369	View/Open

Loading...